Prime Highlights
- LSI Asia’s chief business officer said Singapore’s density of investors, strategics and startups makes high-value dealmaking faster and more efficient.
- Messe Berlin Asia Pacific’s executive director called Singapore a strategic hub where global ideas take shape and scale regionally.
Key Facts
- Singapore holds over a quarter of Southeast Asia’s medtech output, with 60% exported globally.
- The Asia Bio Partnering Forum’s 2025 edition connected 650-plus leaders from 30 countries in over 2,500 one-to-one meetings.
Background
Singapore is pulling ahead as the region’s most active centre for healthcare collaboration, backed by government funding, a strong regulatory system, and a growing list of major industry events that bring global players together.
The government has set aside S$37 billion over five years through its Research, Innovation and Enterprise 2030 plan. The money goes toward turning scientific work into practical healthcare solutions. On the regulatory side, Singapore’s Health Sciences Authority became the first in ASEAN to earn the World Health Organisation’s top rating for medical device oversight. Its clinical trial setup can also cut development timelines from ten years down to three to five.
These foundations have made Singapore a natural draw for big industry gatherings. LSI Asia, a medtech summit focused on connecting startups with investors, pulled in more than 400 executives at its first Asian edition. Companies that presented there were collectively looking to raise over S$1 billion. The event returns in 2026. Medical Fair Asia, the largest healthcare trade show in the region, also adds REHACARE Asia to its 2026 edition, targeting the rehabilitation and assistive technology space.
Digital health is gaining ground, too. The venture capital invested in the region in the sector for the second quarter of 2025 amounts to $1.2 billion, of which artificial intelligence firms absorb about 63 percent. The launch of Smart Health Asia will take place in July 2026, and the number of participants expected is 140 speakers and over 200 exhibitors.
The biopharmaceutical manufacturing capability in Singapore has risen by two times over the past two decades and stands at $13.9 billion in 2023.
